Testing MB-105 for CD5 positive T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of T-cell lymphoma that is CD5 positive, meaning at least half of your cancer cells have the CD5 marker.
- Your cancer has come back or not responded after at least 1 or 2 prior treatments (depending on the type).
- You must be able to undergo a biopsy or have tumor tissue available for testing.
- You need to be in fairly good health, able to care for yourself, and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
Hear when a new Lymphoma, T-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.